RHN001-Dx (⁹⁹ᵐTc-PSMA)
PSMA-positive prostate cancer (imaging)
Phase 1Active
Key Facts
About Rhine Pharma
Rhine Pharma is a private, pre-revenue biotech spin-out from Telix Pharmaceuticals and Heidelberg University Hospital, specializing in accessible radiotheranostics. Its core strategy leverages generator-produced isotopes (Rhenium-188 for therapy, Technetium-99m for imaging) to enable decentralized production, particularly beneficial for regions with limited nuclear medicine infrastructure. The company's advanced pipeline is centered on a PSMA-targeting small molecule, with its therapeutic candidate (RHN001-Tx) currently in a Phase 1/2a clinical trial in South Africa.
View full company profile